

**TIOTROPIUM + OLODATEROL RESPIMAT®
FIXED-DOSE COMBINATION (FDC)*
TOVITO™ PHASE III CLINICAL TRIAL PROGRAMME**



<p>Trial endpoints:</p> <ul style="list-style-type: none"> Lung function Quality of life Exercise Activity Lung function vs. ICS/LABA 	<ul style="list-style-type: none"> Number of patients Length of trial (weeks) 	<ul style="list-style-type: none"> Pivotal Phase IIIa Phase IIIb
--	---	--

* The fixed-dose combination of tiotropium + olodaterol is an investigational treatment. Its safety and efficacy have not yet been fully established.